EXACT Therapeutics AS

OB:EXTX Stock Report

Market Cap: NOK 121.3m

EXACT Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Per Walday

Chief executive officer

NOK 2.8m

Total compensation

CEO salary percentage80.2%
CEO tenure2.6yrs
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Aug 09
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

Apr 20
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Sep 07
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

May 06
We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Dec 30
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15
Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Jan 31
EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Aug 21
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

May 21
We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

CEO Compensation Analysis

How has Per Walday's remuneration changed compared to EXACT Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-NOK 55m

Mar 31 2024n/an/a

-NOK 52m

Dec 31 2023NOK 3mNOK 2m

-NOK 48m

Sep 30 2023n/an/a

-NOK 42m

Jun 30 2023n/an/a

-NOK 36m

Mar 31 2023n/an/a

-NOK 38m

Dec 31 2022NOK 2mNOK 1m

-NOK 40m

Compensation vs Market: Per's total compensation ($USD249.48K) is about average for companies of similar size in the Norwegian market ($USD282.92K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.

CEO

Per Walday (64 yo)

2.6yrs

Tenure

NOK 2,833,302

Compensation

Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since June 5, 2022.Dr. Walday had been the Chief Exe...

Leadership Team

NamePositionTenureCompensationOwnership
Per Walday
Chief Executive Officer2.6yrsNOK 2.83mno data
Svein Kvåle
Co Founder & COOno dataNOK 1.65m9.43%
NOK 11.4m
John Edminson
Chief Financial Officer2.3yrsNOK 2.02mno data
Masha Paule Nathalie Stromme
Director2.6yrsNOK 445.00kno data
Amir Snapir
Chief Medical Officer2.3yrsNOK 2.66mno data
Caspar Foghsgaard
Chief Business Officer1.2yrsNOK 250.00kno data
Per Sontum
Founderno dataNOK 2.49m5.99%
NOK 7.3m
Ragnar Bendicksen
Vice President of Technology2.8yrsno datano data

2.5yrs

Average Tenure

Experienced Management: EXTX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Masha Paule Nathalie Stromme
Director10yrsNOK 445.00kno data
William Castell
Director7yrsNOK 275.00k1.05%
NOK 1.3m
Anders Wold
Chair of the Board3.1yrsNOK 510.00kno data
Jonathan Allis
Vice Chairmanless than a yearno datano data
Ann-Tove Kongsnes
Director3.6yrsNOK 260.00kno data
Flavien Daloz
Directorless than a yearno datano data

3.3yrs

Average Tenure

66yo

Average Age

Experienced Board: EXTX's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:21
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EXACT Therapeutics AS is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution